
Behind the Money
From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world. Hosted on Acast. See acast.com/privacy for more information.
Latest episodes

Feb 28, 2024 • 18min
Is OpenAI’s business model sustainable?
Explore the sustainability of OpenAI’s business model, focusing on the costs of AI technology. Can the start-up achieve its ambitious goals? Discover their revenue strategies and the challenges of balancing profitability with AGI development. Learn about their financial viability and future prospects in the evolving market.

Feb 21, 2024 • 17min
Hedge fund pioneers face signs of a reckoning
Billionaire financier Ken Griffin discusses cracks in the hedge fund sector as Citadel's success faces challenges. The episode explores the rise of multi-manager hedge funds, fundraising struggles, high returns, high costs, market risks, and future scenarios for hedge funds amidst higher interest rates and investor preferences.

Feb 14, 2024 • 16min
Why Elon Musk is breaking up with Delaware
Exploring Delaware's popularity for company incorporation among Fortune 500 companies, particularly Elon Musk's frustration after a Delaware court annulled his $56 billion pay package from Tesla. The significance of Delaware's Court of Chancery in attracting companies, ruling on shareholder lawsuits, efficiency in M&A and proxy fights, and its historical roots. The implications of Elon Musk moving Tesla's incorporation to Texas and the challenges for the Texas Business Court. Elon Musk's decision to relocate Neuralink's incorporation to Nevada and its implications for Delaware and Nevada's reputation for controlling shareholders.

5 snips
Feb 7, 2024 • 17min
Baidu’s ‘do-or-die’ bet on AI
Baidu's struggle to keep up with competitors, their 'do-or-die' bet on AI, the use of Ernie in their AI projects, the reception and challenges of Baidu's AI project in China, and the future of their AI bet

4 snips
Jan 31, 2024 • 16min
Is this nuclear power’s moment?
The podcast discusses the recent attention and challenges faced by the nuclear power industry. Topics include new technological advancements, venture capital investments, boom-and-bust cycles, and controversies. It explores the reliability of nuclear power, development of Small Modular Reactor (SMR) technology, challenges in the US nuclear fuel supply chain, and difficulties in attracting investments. The importance of scaling up SMRs and government support are also highlighted.

Jan 30, 2024 • 1min
Introducing: Swamp Notes from The FT News Briefing
Analyzing the 2024 US Presidential Election including polling numbers, campaign strategies, and legal battles. Introducing a new podcast that explores motivations of presidential candidates beyond the horse race and offers a global perspective.

14 snips
Jan 24, 2024 • 17min
BlackRock goes all in on infrastructure
BlackRock's CEO Larry Fink discusses the acquisition of Global Infrastructure Partners and its impact on the private capital industry. They explore the journey of GIP's founder Adebayo Ogunlacey and the challenges faced by the industry due to rising interest rates. The podcast also highlights the growing popularity of unlisted investments and their potential inclusion in retirement plans.

Jan 17, 2024 • 18min
An IPO drought pushes investors to a murky marketplace
This podcast discusses the rise of venture secondary markets as IPOs and acquisitions slow down in Silicon Valley. It explores the challenges and differences of trading in these markets, the creation of Carter X to simplify share selling, a scandal involving startup Carter, and the lack of transparency in the trade and venture secondaries market.

Jan 11, 2024 • 2min
Introducing Untold: The Retreat
The podcast explores the intense and sometimes difficult experiences that participants face at a meditation retreat, including feelings of terror and a break with reality. Despite these challenges, leaving the retreat is discouraged.

5 snips
Jan 10, 2024 • 21min
Ozempic’s unconventional origins
Explore Novo Nordisk's labs and the development of ozempic and wegovy, the challenges and success of Novo Nordisk, and the company's unique ownership structure. Also, discuss the future prospects and challenges faced by Novo Nordisk, and the benefits and risks of taking a long-term approach in the pharmaceutical industry.